Business News • PR NewsWire • Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology

Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology

Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology

MENLO PARK, Calif., May 2, 2018 /PRNewswire/ -- Refuge Biotechnologies, Inc. ("Refuge"), a company leveraging gene engineering technologies to develop intelligent cell therapeutics programmed to make decisions inside of patients, today announced the closing of a $25 million Series B...

View More : https://www.prnewswire.com/news-releases/refuge-biotechnologies-completes-25-million-series-b-financing-appoints-cso-to-...

Releted News by prnewswire

New Research Shows Promising Signs in Anti-Aging for Araim Pharmaceuticals

Camino Options Villa Hermosa Gold Project in La Libertad, Peru

Nornickel y Euronews presentan un proyecto intercultural internacional

Sheet Face Mask Market Benefiting From Evolving Beauty Practices Worldwide, to Exhibit Robust Growth

SmartClarity [TM] Series has introduced a new member to the line-up, starlight class 1080P CMOS imaging sensor SC2310 debuts at ISC West 2018